In hypertension, the presence of left ventricular hypertrophy (LVH) is associated with increased risk of both cardiovascular morbidity and mortality. To date, the electrocardiogram (ECG) remains the cornerstone of LVH diagnosis in clinical practice because it is universally available, technically easy to perform and highly specific. In the most recent European Society of Hypertension/European Society of Cardiology guidelines for the treatment of arterial hypertension, the Sokolow-Lyon voltage criterion was recommended as part of all routine assessment of subjects with hypertension. However, the use of the ECG in the diagnosis of LVH is somewhat limited by its poor sensitivity. In this review article, we discuss the individual strength and weaknesses of the commonly used ECG criteria in diagnosing LVH. In addition, we present the latest data on the prognostic significance of ECG LVH and the survival differences conferred in different genders. In view of the recent Losartan Intervention for Endpoint Reduction in Hypertension trial, the prognostic benefit of LVH regression will also be addressed. Finally, with the wider availability of echocardiography, the role of combining both modalities to improve risk stratification in hypertension is reviewed.
Introduction
Left ventricular hypertrophy (LVH) diagnosed on electrocardiography (ECG) is an ominous prognostic sign that predicts a high rate of cardiovascular (CV) events. In hypertension, this condition is of particular importance because it helps guide risk stratification. Various ECG criteria for diagnosing LVH exist (Table 1) . They range from the more widely employed fixed voltage criteria like the SokolowLyon criterion (sum of SV1 þ RV5X3.5 mV or max RV5/6X2.6 mV), the McPhie criterion (the sum of the tallest R and deepest S in the precordial leadsX4.5 mV) and the gender-specific Cornell voltage (sum of leads RaVL þ SV3X2.8 mV in men andX2.0 mV in women) to the more complicated Romhilt-Estes score of five points or more, which combines QRS voltage and voltage-independent signs (QRS duration, intrinsicoid deflection in V5 or V6, left atrial enlargement, left-axis deviation and left ventricular (LV) strain). Figure 1 illustrates an example of how these commonly used ECG criteria are calculated.
How good is the ECG in detecting true anatomic LVH?
One major limitation of the ECG is its low sensitivity for detection of LVH. 1 For example, the prevalence of ECG-LVH detected by the Framingham method in the general population was only 2%, which compared with a prevalence of 20% when echocardiography was used. 2, 3 The sensitivity of the ECG is also dependant on the population in which it is applied. Although the sensitivity of several ECG criteria for LVH may be acceptable, albeit low (from 58% for the Romhilt-Estes score 4 to 41% for the Cornell voltage 5 ), among patients with disparate cardiac conditions, the sensitivity of the ECG consistently decreases in the general population. For example, the sensitivity of the Cornell voltage criterion was only 10% in men and 22% in women in the Framingham Heart Study 2 and only 12% in men and 19% in women in the Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) study. 6 In a longitudinal study involving 923 untreated hypertensive participants, Schillaci et al. 7 showed that the performance of the Cornell voltage was superior to the Sokolow-Lyon voltage criterion in predicting echo LVH. In addition, a modified sex-specific partition value of the Cornell voltage (2.4 mV in men and 2.0 mV in women) further improved its predictive value. Subsequent studies evaluated the inclusion of conduction abnormalities with voltage criteria to improve the sensitivity of the ECG. The Cornell voltage duration product (Cornell voltage Â QRS duration) further enhances sensitivity of the ECG while maintaining high specificity, with a sensitivity of 51 versus 31% for Sokolow-Lyon voltage criterion when examined at a matched specificity of 95%. 8 Despite this, the original Sokolow-Lyon voltage criterion 9 is the still the most commonly used ECG criterion because more complex criteria and scoring systems are difficult to apply in clinical practice. The Sokolow-Lyon voltage criterion was successfully used together with the Cornell voltage duration product in detecting patients with LVH in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. On the basis of the LIFE study, the European Society of Hypertension guidelines recommend the use of the Sokolow-Lyon voltage criterion and the Cornell voltage duration product for the assessment of LVH.
10 A summary of the epidemiology studies employing various ECG LVH methods in identifying anatomic LVH is shown in Table 2 .
Voltage ECG LVH criteria as a prognostic indicator
There have been a number of large population-based epidemiological studies and studies in hypertensive cohorts that have assessed the risk associated with ECG-LVH and these have reinforced in general, the prognostic value of ECG-LVH. The prevalence of ECG-LVH and the estimates of risk associated with ECG-LVH vary however, quite considerably in these studies and the variability of these estimates is related to the different populations studied and the differences in the diagnostic criteria used to define ECG-LVH and to define the clinical end points of interest. Furthermore, in most of these studies, the number of individuals with ECG-LVH and the number of outcome events were relatively small, accounting for difficulties in obtaining precise estimates of risk, in spite of the large number of subjects studied and the prolonged periods of follow-up. It should be noted that there have only been a few published reports on the risk associated with ECG-LVH based solely on the Sokolow-Lyon voltage criterion. The seminal data for the prognostic value of the ECG (Sokolow-Lyon voltage criterion) came from the Framingham Heart Study more than 35 years ago. 16, 17 In this longitudinal population-based study, the risk of fatal and nonfatal CV morbid events increased from threefold to eightfold higher in middle-aged persons with ECG-LVH compared to normal adults of similar age, and this finding remained significant after adjustment for coexistent risk factors. It should be noted that these findings relate to ST-T abnormalities (LV strain defined as ST-J point depressionX0.1 mV þ inverted 12 In this landmark trial, LVH defined solely by the Sokolow-Lyon voltage criterion was found to be an independent predictor of all cause deaths, CV death and heart failure. 12 The association with risk of heart failure was particularly pronounced (a twofold increase), considering the fact that all patients had normal LV ejection fraction at study entry. A link between diastolic dysfunction and ECG LVH was postulated. In the PIUMA study, the prognostic role of the Sokolow-Lyon voltage criterion was less convincing. When compared with various other ECG LVH criteria, the Sokolow-Lyon voltage criterion yielded the lowest hazard ratio (HR 1.19) in predicting fatal CV morbid events among hypertensive subjects. This was in contrast with other more predictive methods like the Cornell voltage (HR 1.34) and Romhilt-Estes score (HR 2.63). 6 In this study the Perugia score carried the highest population-attributable risk for CV morbidity and mortality compared with classic methods for detection of LVH ( Figure 2) .
In addition to employing conventional cut-points to define LVH, the application of the voltage criteria as a continuous variable has also been evaluated as a continuous prognostic indicator. In the LIFE study, every 5 mm increase in the Sokolow-Lyon voltage was associated with a significant increase in both CV mortality and morbidity. This also applied to increasing Cornell voltage duration product. Consequently, less severe ECG LVH using the above methods translated to a reduced likelihood of subsequent events. 18 It is fair to say that the prognostic value of an increase in voltage is not new as the Framingham Heart Study had previously shown that patients who were diagnosed with LVH at baseline and went on to develop increasing ECG voltage or re-polarization abnormalities had an increased risk of subsequent CV disease events. 19 Nevertheless, it is important to note that previous evidence has not consistently demonstrated the increased risk of CV mortality associated with voltage-only LVH criteria. In the Copenhagen City Heart Study (a population-based study), men younger than 55 years of age with voltage-only LVH (employing the Minnesota code) had the same risk of developing future coronary artery disease and myocardial infarction as those with a normal ECG. 13 This 20 In addition, the Framingham investigators found that the excess CV risk associated with voltage-only LVH was eliminated when adjusted for hypertension. 21 They postulated that the voltageonly LVH in hypertensive individuals reflects chiefly the severity and duration of the associated hypertension and therefore signifies ventricular muscle hypertrophy without myocardial damage.
Left ventricular strain pattern as a prognostic indicator
Although the evidence regarding the association between voltage-only LVH criteria and adverse clinical outcomes is less robust, there is good evidence to consistently show a strong relationship between the presence of both voltage and repolarization abnormalities and CV mortality. In a recent longitudinal study evaluating 19 434 male patients with a mean follow-up of 7±4 years, the presence of LV strain pattern in addition to voltage criteria yielded an HR of 3.9 after adjustment for conventional cardiac risk factors. 20 In Framingham, the presence of a strain pattern on ECG was the most important predictor of future CV disease across all age and sex. 21 In LIFE, ECG strain was a significant predictor of CV death, non-fatal myocardial infarction or stroke after adjustment for standard CV risk factors, baseline blood pressure (BP) and severity of ECG LVH in the setting of aggressive BP lowering 22 ( Figure 3 ). ECG strain also identified hypertensive patients in LIFE who were at increased risk of developing chronic heart failure (CHF) and dying as a result of CHF. 11 Numerous mechanisms have been postulated to account for the strong association between re-polarization abnormalities and increased CV mortality. One possible mechanism is the development of myocardial fibrosis. Evidence suggests that myocardial fibrosis may impair microvascular coronary reserve, leading to ischaemia. 23 Offering support to this observation is a study which The rate of major CV morbid events was significantly higher in the subset with LVH (with permission from Verdechia et al. 6 ).
demonstrated that patients with LV strain experienced more episodes of exercise-induced ECG abnormalities and more reversible thallium perfusion abnormalities. 24 In addition to myocardial ischaemia, LV systolic dysfunction characterized by lower stress-corrected midwall shortening was also more prevalent in patients with ECG strain pattern. 25 On the contrary, the relationship between strain pattern and LV diastolic abnormalities is weak. In a recent subgroup of the LIFE study, a combination of diastolic parameters (E/A ratio, E wave deceleration time, atrial filling fraction and isovolumic relaxation time) and different LV filling patterns (normal filling pattern, abnormal relaxation, pseudonormal filling pattern and restrictive pattern) assessed by means of Doppler echocardiography did not differ significantly between patients with versus those without strain pattern. 26 
Prolonged QTc and QRS duration predicts prognosis
In addition to the conventional voltage LVH criteria and strain pattern, recent studies have also confirmed the role of QRS and QT prolongation in the risk stratification of hypertensive patients. In the PIUMA study, Schillaci et al. 27 studied 2110 hypertensive patients over a mean duration of 5.3 years. This study found a significant but weak association between corrected QT interval (QTc) and the Cornell voltage (r ¼ 0.06, P ¼ 0.006). In addition, the presence of prolonged QTc (defined asX450 ms in women andX440 ms in men) was associated with a twofold increase in risk of coronary events and CV deaths, independent of traditional cardiac risk factors and ECG LVH. In the LIFE study, prolonged QRS duration further risk stratified patients with established ECG LVH. In this study, increased QRS duration was an independent predictor of both CV and all cause mortality. 28 
ECG LVH and prognosis: does gender matter?
It is important to note that the majority of available ECG LVH criteria do not employ gender-specific cutoffs. This is contrary to the definition of echocardiographic LVH that frequently incorporates different LV mass cut-offs for men and women. The Cornell voltage criterion, which has been shown in some studies to be superior to the Sokolow-Lyon voltage criterion 7 is the only method that employs sexspecific cut-offs. In a recent study, the sensitivity and specificity of four ECG criteria were evaluated against LV mass measured by cardiac MRI. 29 At a matched specificity of 95%, the Sokolow-Lyon voltage criterion yielded the highest sensitivity in women (26.2%), the Cornell voltage criterion had the highest sensitivity in men (26.2%) and the Cornell product criterion had a relatively high sensitivity in both men and women (25 and 23.8%).
Few studies have specifically addressed the differential prognostic value of LVH in men and women. Recent literature suggests that increased LV mass is a stronger risk factor in women than in men. This is particularly true of echocardiographic (echo) LVH. Liao et al. 30 described an unfavourable prognosis in terms of total death and cardiac-related deaths in black women with echo LVH compared to black men with echo LVH. Data from the Glasgow Blood Pressure Clinic 31 also support this observation of survival disadvantage conferred by LVH in women. In the presence of ECG LVH, women had a substantially higher risk of dying from CV causes. The Framingham Heart Study highlighted an increased risk of stroke and CVD mortality among women with ECG LVH. 32 In a recent prospective study involving 6668 hypertensive patients with a mean follow-up duration of 11.2 years, the Sokolow-Lyon voltage criterion predicted stroke mortality in women but not in men. 33 The difference in survival between genders conferred by ECG LVH has no clear underlying mechanism but a higher prevalence of the concentric geometric abnormality in women than men is a possible explanation. The latter carries the highest risk and eccentric hypertrophy an intermediate risk. 34 
ECG LVH and Echo LVH: is there a role in combining both?
With the wider availability of echocardiography, there may be a role of combining ECG and echo LVH in evaluating prognosis. In the second Strong Heart Study, 2193 American Indians underwent both ECG and echocardiography and were followed up over an average of 3 years. The presence of both echo LVH and ECG ST depression was associated with a 6.3-fold increased of CV death in this group of patients 35 ( Figure 4) . In addition to this, Sundstrom et al. 36 showed that the prognostic value of ECG LVH (employing the Cornell product) to some extent is independent of echocardiographic LV mass index in predicting total mortality in a population-based sample of 475 men. The author concluded that echo LVH and ECG LVH carried different prognostic information. 36 The combination of ECG and echo LVH also predicted future risks of ischaemic stroke. Kohsaka et al. 37 demonstrated that LVH diagnosed based on the Cornell voltage criteria was associated with an increased risk of ischaemic stroke after adjustment for other stroke risk factors and echo LVH. The author suggested that ECG LVH may detect electrical abnormalities induced by the hypertrophy process that are not detectable by echocardiography, and this information may aid in stroke risk prediction.
ECG LVH regression and prognosis
While the evidence is clear that ECG LVH is linked to adverse clinical outcomes, the question arises as to whether regression or reversal of ECG LVH is associated with improved prognosis. Various observational studies suggest that LVH reversal is beneficial beyond BP reduction and treatment by demonstrating that CV events occur in higher proportion of individuals in whom LVH progresses than regresses. 19, 38 These findings suggest that the level of LV mass during antihypertensive treatment reflects independent information regarding disease progression or its control. Confirmation of this hypothesis comes from two landmark trials; the HOPE and LIFE trials. In LIFE, lower Cornell product and Sokolow-Lyon voltage criterion during antihypertensive treatment were associated with lower risk of CV mortality, myocardial infarctions or strokes. 18 These findings were independent of BP reduction or treatment modalities. In HOPE, treatment with the ACE inhibitor, ramipril in a highrisk cohort was associated with significant regression or prevention of ECG LVH (defined using the Sokolow-Lyon voltage criterion). 39 This was associated with a significant reduction in CV events in the group whereby LVH regression occurred. Therefore, based on these findings it is now evident that reversal of ECG LVH has an independent prognostic value, independent of therapy and BP.
The implications of ECG LVH in clinical practice
On the basis of current evidence, the detection of LVH in hypertension is even more important than before because its reversal is associated with a favourable prognosis. However, the question arises as to how we should detect this condition in the vast number of hypertensive patients based on the available resources. In clinical practice, the ECG is usually the first line of investigation to assess for the presence of LVH in hypertension. The presence of ECG LVH is highly specific of anatomic LVH and hence this subgroup of patients may not need further prognostic evaluation. However, in the group of hypertensive patients without ECG LVH, should physicians be routinely referring all these patients for an echocardiogram? Due to the enhanced sensitivity of the echocardiogram in detecting LVH, the answer is likely to be 'yes' in an ideal world. In addition, the echocardiogram has the advantage of providing a quick and accurate assessment of the valves and LV systolic/diastolic function. However, advocating an echocardiogram for the assessment of LVH in all hypertensive individuals would have enormous cost implications on the National Health Service. This imaging modality is more time consuming and requires considerable skills to perform. Therefore, for the foreseeable future, the combination of the patient's risk factor profile, ECG findings and 24 h ambulatory BP monitoring will be used to guide physicians or general practitioners as to which hypertensive patient merits an echocardiogram for the evaluation of LVH.
Conclusion
In conclusion, the role of the ECG as a prognostic tool in hypertension has been well established and newer evidence continues to strengthen its clinical utility in this respect. In addition, the favourable prognosis associated with ECG LVH regression should further prompt clinicians to actively screen for this condition and implement aggressive secondary prevention therapy when present. With the wider availability of echocardiography, both these noninvasive modalities can be used synergistically to yield prognostic information far beyond the conventional CV risk factors in hypertension. Both ECG LVH and echocardiographic LVH reflect different pathological processes and thereby influence prognosis in different ways. However, for the foreseeable future, the ECG will remain as an important tool for the diagnosis of LVH in hypertension mainly because it is easy to use, highly specific and widely available.
